Please assess the completion status of the following clinical trial:

Trial Title: Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infant 46 to 74 days (both inclusive)~* Documented receipt of only one dose of monovalent hepatitis B vaccine within the 3 days after birth~* Parent(s)/legal representative able to comply with the study procedures~Exclusion Criteria:~* Participation in any study with an investigational compound or device since birth~* History of congenital or acquired immunodeficiency~* Chronic illness that could interfere with study conduct or completion~* Hypersensitivity to any of the study vaccines components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines~* Contraindication to Pediacel®, NeisVac-C®, Prevenar 13®, and RotaTeq®~* History or maternal history of HBsAg seropositivity~* Coagulation disorder that contraindicate intramuscular injection~* History of vaccination with a Haemophilus influenzae type b conjugate, diphtheria, tetanus, pertussis (acelullar or whole-cell), poliovirus, meningococcal serogroup C conjugate, pneumococcal conjugate containing vaccine(s)~* History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliomyelitis, or serogroup C meningococcal infection~* Receipt of immune globulin, blood or blood-derived products since birth~* Receipt of systemic corticosteroids for more than 14 consecutive days within one month of the study start~* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 76 Days
- Healthy Volunteers: t

Study Arms:
- PR5I (V1); Pediacel® (V2); PR5I (V3) (Type: EXPERIMENTAL): \[Vaccination 1\]: Single doses of PR5I (V419) + NeisVac-C® + Prevenar 13® by intramuscular (IM) injection + oral RotaTeq®, given at 2 months of age. \[Vaccination 2\]: Single doses of Pediacel® + NeisVac-C® + Prevenar 13® by IM injection + oral RotaTeq®, given at 4 months of age. \[Vaccination 3\]: Single dose of PR5I (V419) by IM injection + oral RotaTeq®, given at 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).